Multiple Sclerosis Research

The Multiple Sclerosis Clinic at UMass Memorial Health Care participates in many clinical trials to evaluate the effectiveness of a variety of drugs and treatments for MS. Currently it is the site of several different clinical trials involving patients with Relapsing Remitting, Secondary Progressive, and Primary Progressive MS. We are involved in trials to prevent the future worsening of MS, and to improve the quality of life of our patients.

Along with clinical trials, we are also involved in several clinical research studies which are aimed at finding the cause or causes of the MS. These studies generally require only one clinic visit and may allow family members to participate by donating blood and filling our questionnaires.

For information on any of these trials please contact the call center at (508) 793-6561 and ask for Carolyn Griffin RN, BNS, CCRP.

ACT-128800

Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis

Sponsor: Actelion

Status: Open, Recruiting New Patients

 

Inclusion/Exclusion Criteria

 


ADVANCE Study

Length of Study 2 Years

A Multicenter, Randomized, Double-Blind, Parellel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Sclerosis

Sponsor: Biogen Idec

Status: Open, Recruiting New Patients

Inclusion/Exclusion Criteria

 

ACCELERATED CURE PROJECT 

A Longitudinal, Case-Control Study to Collect Medical and Epidemiological Data and Blood Samples for Research Into the Causes of Multiple Sclerosis and Selected Demyelinating Diseases.  

Status:  Open to subjects with all forms of MS and demyelinating diseases as well as up to 2 healthy first degree blood relatives. 

Inclusion/Exclusion Criteria 

Note: For information on this study, contact Jan Weaver at (508) 793-6562 

Web Site:   http://www.acceleratedcure.org/

CARE-MS I Study

Length of study 2-4 years

A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients with Relapsing-Remitting Multiple Sclerosis

Sponsor: Genzyme

Status:  Open, recruitment closed

CARE-MS II Study

Length of Study 2-4 years

A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weely Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Sclerosis Who Have Relapsed on Therapy.

Sponsor: Genzyme

Status: Open, recruitment closed

 CombiRx Study 

Length of study 3 years 

A Multi-Centered, Double-Blind, Randomized NIH Sponsored Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis (CombiRX-Phase III) 

Status:  Open, recruitment closed

NINDS Biomarkers in Multiple Sclerosis Study (BioMS) 

Open to Subjects Enrolled in CombiRx Study 

 FREEDOMS II Study 

Length of study 2 years 

A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parellel-Group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients with Relapsing-Remitting Multiple Sclerosis. 

Sponsor: Novartis Pharmaceuticals 

Status: Open, recruitment closed

DEFINE Study

Length of study:  2 years

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis. 

Sponsor: Biogen Idec

Status: Open, recruitment closed